Shortening the infusion time of anticancer drugs: who will benefit?

J Clin Oncol. 2007 Jul 1;25(19):2642-3. doi: 10.1200/JCO.2007.10.7334.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / economics
  • Bevacizumab
  • Humans
  • Infusions, Intravenous*
  • Medical Oncology / economics
  • Medical Oncology / methods
  • Neoplasms / drug therapy*
  • Prospective Studies
  • Quality of Life
  • Time Factors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Bevacizumab